Esperion Therapeutics Patent-Cliff Exposure & CMS Drug Spending Portfolio

Esperion Therapeutics (US): 2 reconciled FDA prescription therapies, $153.2M 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2040-01-01
2024 CMS Total Public Spend$153.2M
2024 Medicare Part D Spend$141.7M
2024 Medicaid Spend$11.4M
California HCAI SB 17 Filings4 WAC filings (max 20.0% 2-yr change)